MEI Pharma, Inc. (MEIP)
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
$19.86M
Dr. Daniel P. Gold
102.00
San Diego, CA
Dec 18, 2003
0.76
$3.92
0.25
6.17
55.73%
125.01%
39.18%
0.80
0.02
0.41
0.31
6.17
36.70%
48.32%
Similar stocks (16)
Ocular Therapeutix, Inc.
OCUL
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Instil Bio, Inc.
TIL
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
Kezar Life Sciences, Inc.
KZR
Vincerx Pharma, Inc.
VINC
TransCode Therapeutics, Inc.
RNAZ
Avenue Therapeutics, Inc.
ATXI
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
ETF Exposure (1)
Dimensional U.S. Targeted Value ETF
DFAT
2.3972999999999998e-4%
Similar stocks (16)
Ocular Therapeutix, Inc.
OCUL
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Instil Bio, Inc.
TIL
Inozyme Pharma, Inc.
INZY
HOOKIPA Pharma Inc.
HOOK
Acumen Pharmaceuticals, Inc.
ABOS
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
Kezar Life Sciences, Inc.
KZR
Vincerx Pharma, Inc.
VINC
TransCode Therapeutics, Inc.
RNAZ
Avenue Therapeutics, Inc.
ATXI
Revelation Biosciences, Inc.
REVB
Phio Pharmaceuticals Corp.
PHIO
ETF Exposure (1)
Dimensional U.S. Targeted Value ETF
DFAT
2.3972999999999998e-4%